Mitochondrial dysfunction mediated by Bax and Bak is a critical step in mammalian cell apoptosis. However, the molecular mechanism of Bax activation remains unknown and has been difficult to investigate due to its rapid and stochastic nature. It is currently unclear whether mitochondria play a passive role in the initiation of apoptosis, remaining unaffected by cell stresses until Bax and Bak are active, or whether they actively participate in Bax/Bak activation. Here, two viral proteins, E1B19K and BHRF1, are examined for their ability to block Bax activation at different steps and thereby reveal the timing of mitochondrial changes during apoptosis. We demonstrate that BHRF1 strongly inhibits Bax activation but not upstream apoptotic signaling events, while E1B19K permits initial stages of Bax activation but prevents the subsequent oligomerization of Bax that is required for mitochondrial dysfunction. In this defined system we show that changes in mitochondrial ultrastructure, characteristic of cells undergoing apoptosis, precede Bax activation and are not blocked by E1B19K and BHRF1. We suggest that the ability of mitochondria to respond to apoptotic stress prior to Bax activation indicates that these organelles may play a direct role in activating Bax.
Apoptosis is required for correct development and organismal homeostasis, while defects in apoptosis contribute to the progression of cancer and degenerative diseases. The onset of mitochondrial dysfunction, characterized by the loss of mitochondrial membrane potential (Δψm) and the release of mitochondrially sequestered proteins, such as cytochrome c (Cyt-c), has been shown to be a critical control point in the apoptotic program and is followed by activation of cytosolic effector caspases leading to cell death.1
Bcl-2 family proteins have emerged as important regulators of apoptosis since they govern mitochondrial integrity. The pro-apoptotic Bcl-2 family members Bax and Bak are absolutely required for mitochondrial dysfunction during apoptosis and cells isolated from mice deficient in both Bax and Bak are protected from apoptosis, failing to release Cyt-c in response to diverse apoptotic stimuli. In healthy cells, Bax is a predominantly cytoplasmic protein, while Bak is constitutively localized to mitochondria. During apoptosis both proteins undergo conformational change, including at their N termini,2, 3 to become active and enter into mitochondrially associated foci.4 This correlates with the onset of mitochondrial dysfunction, loss of Δψm and release of Cyt-c.
Pro-survival members of the Bcl-2 family, such as Bcl-2 and Bcl-XL, act to oppose Bax and Bak activation whereas a further group of pro-apoptotic Bcl-2 proteins, the BH3-only proteins, are activated by diverse cellular stresses and can bind and inactivate the Bcl-2 pro-survival proteins.5 BH3-only proteins, most notably tBid, can also interact with Bax and Bak and result in their direct activation,6 although this interaction has been difficult to detect in vivo.7 In addition to their role in binding BH3-only proteins, Bcl-2 pro-survival proteins can function to directly bind and hold Bak inactive.8 However, a large fraction of the cellular pool of Bax is cytoplasmic and monomeric,9 and so a directly analogous mechanism by which Bax is held in check by the predominantly membrane-bound Bcl-2 pro-survival proteins seems unlikely. Therefore both the mechanism by which Bax is initially activated in cells undergoing apoptosis and the connection between inhibition of the pro-survival Bcl-2 proteins by BH3-only proteins and the promotion of Bax activation, still remain unclear.
Many viruses have developed strategies to modulate the apoptotic signaling pathways of infected host cells to promote productive infection.10 Some viral pro-survival proteins, such as Epstein–Barr virus BHRF1 and human herpes virus 8 vBCL-2, share structural and sequence homology with cellular Bcl-2 proteins.11 Others, such as adenovirus E1B19K, vaccinia virus F1L, human cytomegalovirus vMIA and myxoma virus M11L, share very low or no sequence homology with Bcl-2 proteins, but are nevertheless able to directly target and inhibit Bax and Bak oligomerization.12, 13, 14, 15, 16, 17 M11L has structural homology to Bcl-2 proteins despite a lack of sequence homology18 but structures are not yet available for other viral inhibitors of Bax/Bak. E1B19K is particularly interesting since it blocks apoptosis in infected cells by binding Bax and Bak, preventing their oligomerization and association.12, 19, 20, 21
Physical changes in mitochondrial ultrastructure have been seen in both purified mitochondria and intact cells undergoing changes in metabolism.22, 23, 24 Similar changes have been observed during apoptosis,25, 26, 27 however, these changes have yet to be correlated with Bax activation status. It is therefore unclear whether changes in mitochondrial structure during apoptosis are a secondary response to Bax and Bak activation, occurring only in cells committed to die, or can occur prior to Bax/Bak activation.
We initially used live cell video microscopy to reveal there is heterogeneity in the timing of Bax activation both at the single cell and population level. This rapid and asynchronous nature of Bax activation confounds a detailed characterization of exactly when mitochondrial ultrastructural changes first occur. We reasoned that viral proteins that can inhibit Bax/Bak activation would provide a strategy to block mitochondrial dysfunction and thereby observe when mitochondria respond to pro-apoptotic signals. Such an approach eliminates the need to rely on cells that may have adapted to the genetic absence of Bax and Bak, or the consequent predominance of pro-survival Bcl-2 proteins. We show that mitochondrial remodeling and matrix condensation occurs in response to the apoptotic stimulus independently of Bax and Bak activation. We suggest that if mitochondria can respond to the stress of an apoptotic insult even when Bax and Bak are blocked by viral proteins, then such changes could contribute to Bax/Bak activation in the absence of viral proteins.
During apoptosis Bax and Bak undergo a dramatic conformational change and enter into mitochondrially associated foci. Bax tagged at the N-terminus with GFP can be used to visualize this process in live cells. U2OS human osteosarcoma cells or MCF10A human untransformed immortalized breast epithelial cells were transfected with GFP-Bax and 24 h later cells were loaded with TMRE to visualize the location of energized mitochondria. Cells were then treated with UV irradiation or with an activating antibody against the Fas death receptor together with cycloheximide (FasL/CHX), to induce apoptosis. In all conditions tested, GFP-Bax activation occurred stochastically throughout the cell population and was characterized by the sudden and rapid redistribution of GFP-Bax into mitochondrially associated foci and coincident mitochondrial dysfunction, as measured by a loss of Δψm (Figure 1a). Complete loss of Δψm occurred within an ∼5-min period although this was composed of the very rapid (<1 min) loss of Δψm at individual mitochondria combined with a degree of heterogeneity in the timing at which loss of Δψm occurred at different mitochondria in the same cell (Figure 1a, Videos 1–3). In some cases GFP-Bax activation in one part of the cell could precede the activation in a neighboring subcellular region. An extreme example is shown in Figure 1b, Video 4 where GFP-Bax first becomes active in a peripheral region, separated from the main cell body by a narrow cytoplasmic projection (Figure 1b, 381/431 min). This cell underwent morphological changes such that the region containing active Bax retracted inwards towards the main cell body, leading to rapid activation of GFP-Bax and loss of Δψm throughout the rest of the cell (Figure 1b, 528/529 min). These observations demonstrate that Bax activation is a rapid and coordinated event at the single cell level but there can be some heterogeneity in exact timing of individual mitochondria losing Δψm.
We next wanted to investigate the effect of Bax activation on mitochondrial ultrastructure and in particular to address whether mitochondria respond to an apoptotic stimulus prior to Bax activation. Such analysis is complicated by the rapid and asynchronous nature of apoptotic cell deaths. At the level of a cell population most cells have either yet to initiate Bax activation or have progressed rapidly through to become late stage apoptotic bodies. In addition, identifying cells in the earliest stages of Bax activation in samples imaged by electron microscopy for ultrastructural analysis remains technically challenging.
We therefore sought to determine whether viral proteins that protect cells against apoptosis could be used to further dissect the relationship between Bax activation and mitochondrial dysfunction. We selected two viral proteins: BHRF1 from Epstein–Barr virus is a Bcl-2 sequence homolog and E1B19K from adenovirus, which has very limited sequence homology to the cellular Bcl-2 proteins but still protects against apoptosis.11 E1B19K and BHRF1 were stably expressed in MCF10A cells by retroviral transduction and control cell lines were generated over-expressing the cellular pro-survival proteins Bcl-2 and Bcl-XL, or infected with empty retrovirus (Figure 2a). Cells were treated with FasL/CHX, a physiologically relevant stimulus since virally infected cells are targeted by the immune system through activation of TNF family receptors including Fas. Apoptosis was quantified by measuring the proportion of cells with fragmented (sub-G1) DNA content (Figure 2b). Overexpression of Bcl-2 and Bcl-XL provided moderate protection to the cells relative to empty vector control cells, however, expression of either E1B19K or BHRF1 was strongly protective and the majority of cells were still alive after more than 14 h (Figure 2b). Western blot analysis of whole cell lysates revealed that events downstream of death receptor activation, but upstream of the mitochondria – the processing of pro-caspase-8, the cleavage of full length Bid and the caspase-8 dependent cleavage of the pro-form of casapse-3 – all proceeded at the same rate in all cells, independently of the presence of pro-survival proteins (Figure 2c; pre-mitochondrial). However, events downstream of mitochondria – the processing of pro-caspase-9 and the cleavage of DNA repair enzyme poly (ADP-ribose) polymerase-1 (PARP), a classical marker for apoptosis – occurred only in cell lines where significant death was also observed and was almost completely blocked by expression of E1B19K and BHRF1 (Figure 2c; post-mitochondrial). The caspase-8-dependent cleavage of pro-caspase-3 was evident in all cells; however, this was not always sufficient to generate effector caspase activity and further caspase-9-dependent processing from p20 to p17 was required for full activation (Figure 2c), a similar observation has been made in other systems.19 Together, these results demonstrate that while overexpression of Bcl-2 and Bcl-XL offers MCF10A cells modest protection against FasL/CHX-induced apoptosis, the viral proteins E1B19K and BHRF1 offered much greater protection and are acting at the level of the mitochondria.
We next sought to determine the Bax activation status in cells protected by the viral pro-survival proteins. Antibodies raised again the N-terminus of Bax and Bak are conformationally sensitive and recognize only the active form of the proteins.2, 3 Cells were treated with FasL/CHX and Bax activation was assessed by immunoprecipitation using a conformationally sensitive anti-Bax N20 antibody. In control cells Bax becomes active and coimmunoprecipitates Bak, indicating the formation of Bax/Bak heterodimers and heteroligomers, whereas in cells expressing BHRF1 Bax conformational change was blocked and Bax failed to immunoprecipitate (Figure 3a). Strikingly E1B19K-expressing cells showed significant conformational activation of Bax, but with minimal coassociation of Bak, indicating that Bax/Bak oligomerization may be blocked (Figure 3a). Immunofluorescence analysis of FasL/CHX treated cells using the same Bax antibody and an antibody against Cyt-c showed many control cells exhibited bright foci indicative of active Bax and associated release of Cyt-c while BHRF1-expressing cells did not stain for active Bax (Figure 3b). In E1B19K-expressing cells, Bax was recognized by the N20 antibody but showed an even mitochondrial distribution and was not localized into punctate foci characteristic of fully active Bax. Cyt-c retained a mitochondrial distribution in E1B19K- and BHRF1-expressing cells (Figure 3b). Similar results were obtained using UV irradiation to induce apoptosis in MCF10A cells and in U2OS osteosarcoma cells and IMR90 primary human fibroblasts stably expressing E1B19K and BHRF1 (data not shown). The proportion of MCF10A cells staining with anti-Bax N20 increased with the duration of FasL/CHX treatment, with most E1B19K-expressing cells staining positive for active Bax but without Cyt-c release after 12 h, correlating with maximum Bax activation as detected by immunoprecipitation (Figure 3a and data not shown). To confirm that Bax oligomerization was indeed blocked in the E1B19K- and BHRF1-expressing cells and these results were not due to masking of the N20 epitope, lysates were analyzed by size exclusion chromatography for the molecular weight distribution of total Bax. Bax moves into a high molecular weight range in control cells treated with FasL/CHX, and both viral proteins prevented this shift (Figure 3c).
Unlike Bax, Bak is constitutively localized to the mitochondria and therefore Bak activation does not require translocation. Bak also exhibits an N-terminal conformational change and coimmunostaining of Fas/CHX-treated cells with anti-Bak NT and anti-Cyt-c revealed that Bak activation was blocked in an analogous manner to Bax; in control cells Bak activation was clearly associated with the formation of bright Bak foci, this occurred stochastically throughout the cell population and correlated with the release of Cyt-c (Figure 4). In BHRF1-expressing cells there was no evidence of Bak activation after 9 h of Fas/CHX treatment, while E1B19K-expressing cells were recognized by the Bak NT antibody but with Bak evenly distributed over the mitochondrial network with no evidence of entry into bright foci or Cyt-c release (Figure 4).
Together, these results demonstrate that expression of BHRF1 strongly inhibits Bax and Bak activation in response to FasL/CHX treatment, but not upstream apoptotic signaling events. E1B19K expression permits the initial N-terminal conformational activation of both Bax and Bak, in agreement with previously published results,12, 19, 20, 21 indicating the apoptotic signal reaches these molecules intact and at approximately the same rate as control cells; however, conformationally active Bax becomes blocked, evenly distributed on the mitochondrial network and fails to form foci or cause the release of Cyt-c.
We next sought to investigate the mechanism by which the viral pro-survival proteins block Bax/Bak activation. The direct binding of E1B19K to N-terminally active Bax can be detected by coimmunoprecipitation (Figure 5a). In addition, an epitope within the α7/α8 (BH2) region of Bax is masked in E1B19K-expressing cells following FasL/CHX treatment, as has been previously reported.20 This could indicate a second conformational change in this region is required for full Bax activation and is prevented by E1B19K, or that this region is masked by direct interaction with E1B19K. At present these possibilities cannot be distinguished. BHRF1 limits Bax activation and strongly suppresses both Bak activation and the coassociation of Bax and Bak (Figure 5b). The anti-Bak NT antibody constitutively recognizes a small pool of Bak, even in untreated cells. BHRF1 coimmunoprecipitates with this Bak and the interaction is increased upon FasL/CHX treatment and could therefore explain how BHRF1 prevents Bak activation. The amount of BHRF1 associated with Bax is much lower and unlikely to fully explain the lack of Bax activation in these cells. In addition, we have observed GFP-Bax remains cytoplasmic in BHRF1 expressing cells following FasL/CHX treatment, while BHRF1 is localized to mitochondria (our unpublished observations), also suggesting it is less likely BHRF1 blocks Bax activation by direct interaction. It is possible BHRF1 protects by binding and sequestering the tBid generated in response to FasL/CHX, but we have been unable to detect Bid or tBid in BHRF1 immunoprecipitations (data not shown). Therefore, BHRF1 can bind and inhibit Bak activation but further work is required to determine how BHRF1 inhibits Bax activation.
Electron microscopy can be used to visualize ultrastructural changes occurring within individual mitochondria but it is difficult to identify cells undergoing the earliest stages of Bax activation due to the asynchronous initiation and rapid progression of this process. We reasoned that the viral proteins characterized above provided an ideal way to accumulate entire populations of cells in which Bax activation was blocked at different stages, and thereby to analyze whether changes in mitochondrial ultrastructure could occur prior to Bax activation. MCF10A cells were therefore treated with FasL/CHX for 12 h and then fixed and stained for EM. Ultrastructural analysis performed in situ eliminates the danger of changes caused by purification of the mitochondria and therefore more clearly demonstrates changes pre-existing in cells before Bax and Bak activation. Changes in the mitochondrial ultrastructure of control cells undergoing apoptosis in response to FasL/CHX were clearly detectable (Figure 6a) and were categorized according to the degree of matrix condensation and remodeling of cristae membranes (Figure 6b). We also noticed the appearance of electron dense granules in the matrix of mitochondria following treatment with FasL/CHX that have been reported previously as precipitates of calcium phosphate28 and have been shown to be reversible in neuronal samples following periods of stimulation.29 The presence of electron dense granules in the present study suggests there has been significant mitochondrial Ca2+ uptake.
After 12 h FasL/CHX treatment there was significant apoptosis in wild type cells, but little detectable cell death in either E1B19K- or BHRF1-expressing populations, although by this time most E1B19K cells have accumulated conformationally active Bax at mitochondria (Figure 7a). Ultrastructural analysis revealed significant remodeling of mitochondria in control cells from Type I to Type IIa/b morphologies (Figure 7b). Remodeling had also taken place in E1B19K- and BHRF1-expressing cells, independently of the stage of Bax and Bak activation (Figure 7b), clearly demonstrating that changes in mitochondrial ultrastructure can precede Bax and Bak activation.
In some systems fragmentation of the mitochondrial network has been observed during apoptosis. In the present study, widespread mitochondrial fragmentation preceding Cyt-c release was not apparent by confocal microscopy and quantification of the number of mitochondria per electron micrograph revealed a modest increase in the number of mitochondria per frame following FasL/CHX treatment (Figure 7c). The presence of electron dense granules in the mitochondrial matrix was also quantified and revealed a dramatic increase following treatment with FasL/CHX (Figure 7d), suggesting significant Ca2+ uptake by mitochondria in response to the FasL/CHX treatment. Importantly, both phenomena occurred in all cell lines regardless of Bax/Bak activation status, thereby providing additional evidence that mitochondria can respond to the stress of an apoptotic stimulus prior to the activation of Bax and Bak.
Bax and Bak are responsible for mitochondrial dysfunction during apoptosis and it is widely assumed that changes in mitochondria occurring during apoptotic cell death are therefore a result of Bax and Bak activation. Bax becomes active in the plane of mitochondrial membranes30 and Bax can pre-exist at mitochondrial membranes without inducing apoptosis.2 Since mitochondrial localization of at least a fraction of the total cellular Bax does not guarantee activation, further events must be necessary. This could involve the insertion of the central helical core of Bax into the membrane to initiate Bax oligomerization.31 It is also possible that mitochondria respond to the stress of an apoptotic insult prior to cell-wide Bax activation and could directly participate in Bax activation.
In the present study, inactivation of Bax and Bak at different steps in the apoptotic program using the viral proteins E1B19K and BHRF1 reveals that changes in mitochondrial ultrastructure can occur independently of Bax and Bak activation (Figure 8). E1B19K acts after the initial conformational activation of both Bax and Bak, and mitochondrial recruitment of Bax, by direct binding to prevent Bax/Bak oligomerization.12, 19, 20, 21 E1B19K therefore allows an activating signal to reach Bax and Bak intact and then blocks cell death by preventing their oligomerization – this may be an efficient step for a viral protein to target, at a point where diverse apoptotic stimuli converge. BHRF1 appears to act earlier, also preventing the N-terminal activation of Bax and Bak. BHRF1 binds Bak and this interaction increases following treatment with FasL/CHX, without an increase in Bak N-terminal activation, in this respect BHRF1 may function in an analogous fashion to Bcl-XL and Mcl-1.8 However, these data do not explain how mitochondrial BHRF1 can prevent activation of cytoplasmic Bax. BHRF1 has a less prominent hydrophobic groove for binding BH3-only members32 and despite being an extremely potent suppressor of Bax/Bak activation, it shows a limited selectivity for BH3-only peptides in vitro.33 Therefore, these data do not exclude BHRF1-mediating a protective effect through additional as yet unidentified targets at the mitochondria.
The majority of Cyt-c is sequestered in the cristae cisternae and tightly associated with cardiolipin34 and tBid can induce remodeling of mitochondrial cristae in the absence of Bax and Bak necessary for complete release of Cyt-c during apoptosis.27 tBid may contribute to the ultrastructural changes observed in the present study as tBid is generated downstream of death receptor activation in both E1B19K- and BHRF1-expressing cells, at levels comparable to that seen in control cells (Figure 2c). However, there are likely to be multiple pathways communicating pro-apoptotic signals to mitochondria, for example, BIK, another BH3-only protein, can induce cristae remodeling mediated by a Ca2+-dependent mechanism.35 Interestingly, electron dense granules, thought to be calcium phosphate precipitates, appear in the mitochondrial matrix of FasL/CHX-treated cells regardless of whether Bax/Bak activation has occurred. There are emerging roles for Bcl-2 family proteins in directly modulating ER Ca2+ dynamics36 and Ca2+ release from intracellular ER stores is known to occur during cellular bioenergetic stress and can act to upregulate energy conserving pathways and ATP production.37 In addition, mitochondria avidly uptake cytosolic Ca2+, upregulating the activity of key mitochondrial dehydrogenases, oxidative metabolism and ATP production.38 The ability of mitochondria to buffer free Ca2+ can be exceeded promoting mitochondrial permeability transition and thereby apoptosis when release of accumulated Ca2+ could result in a feed-forward loop ensuring coordinated recruitment of other mitochondria within the cell. Both inter- and intra-mitochondrial Ca2+ waves have been observed during apoptotic cell death39 and can be modified by the degree of fragmentation of the mitochondrial network.40 In the future it will be important to understand how Bcl-2 pro-survival proteins allow mitochondrial physiological responses to stress to occur, without triggering Bax/Bak activation.
Changes in metabolism have been correlated with changes in mitochondrial ultrastructure, with more condensed matrix and swollen cristae spaces generally indicating more active (ADP-stimulated) oxidative phosphorylation.22, 23, 24, 26 Here, we observe similar changes in apoptotic cells fixed and stained in situ; there is a striking resemblance between the transition from Type I to Type II mitochondria during apoptosis and the transition of mitochondria from ‘orthodox’ to ‘condensed’ morphology observed during metabolic stimulation. These phenomena could be related to upregulation of mitochondrial metabolism and oxidative phosphorylation to provide additional ATP and metabolic intermediates to help combat stress or damage associated with a pro-apoptotic stimulus. Perhaps the duration or extent of the cellular insult, combined with the extent of pro-survival response the cell can mount, is involved in determining whether survival is possible or the cell should commit to apoptosis. If mitochondria respond to cell stress before Bax/Bak activation commits the cell to apoptosis, it raises the possibility of ‘inside-out’ signaling from mitochondria to Bcl-2 family proteins. Viral proteins can act as important tools to delineate such pathways and better understand whether mitochondrial responses prior to Bax/Bak activation play an integrating role in processing pro-apoptotic stress. It could be that primitive adaptive mitochondrial responses to cell stress are now intercepted by Bcl-2 proteins in higher eukaryotes, but further studies are necessary to clarify how mitochondria adapt to pro-apoptotic stress and clarify whether they participate in regulating the activity of Bcl-2 family proteins.
Materials and Methods
Cell lines and induction of apoptosis
U2OS osteosarcoma cells were grown in DMEM+10% fetal bovine serum. MCF10A mammary epithelial cells were grown in Ham's nutrient mixture F-12/DMEM (1:1) supplemented with 5% horse serum and 10 μg/ml insulin, 20 ng/ml EGF, 5 μg/ml hydrocortisone and 100 ng/ml cholera toxin. For cell death treatments minimal medium supplemented with 5% horse serum was used. Retroviral constructs: pBABE puro Bcl-2, pBABE hygro Bcl-XL, pBABE puro E1B19K and pBABE puro BHRF1 were obtained from D Hancock, CR-UK and introduced by retroviral transduction. MCF10A cells were selected with 1 μg/ml puromycin or 300 μg/ml hygromycin B respectively and the presence of the transduced proteins was confirmed by western blotting using anti-Bcl-2 (Santa Cruz), anti-Bcl-XL (Transduction Labs), anti-E1B19K (Oncogene) and anti-BHRF1 (Chemicon) monoclonal antibodies. The resulting stable cell lines were used for all subsequent experiments in this study. For induction of apoptosis by UV irradiation cells were exposed to 30 J/m2 UVC in a UV crosslinker (Hoefer). For FasL/CHX treatments anti-Fas IgM clone CH11 (Upstate) was used at a final concentration of 250 ng/ml with 2 μg/ml CHX.
Live cell video microscopy
For live cell microscopy the indicated cell lines were seeded in 35 mm glass bottomed dishes (MatTek). 24 h later cells were transfected with GFP-Bax (a gift from R Youle, NIH) using Effectene (Qiagen). After a further 24 h, cells were loaded with 2 nM tetramethylrhodamine methyl ester (TMRE, Molecular Probes) phenol red-free added to the growth media for 20 min. Cells were washed and phenol red-free media added together with the indicated treatment to induce apoptosis. All time-lapse experiments were conducted on a Zeiss Axiovert 135 TV inverted microscope (Carl Zeiss) under the control of AQM image acquisition software (Kinetic Imaging). Filters and dichromatic mirrors were purchased from Omega Optical Inc. and permitted the detection of EGFP and TMRE. The microscope was housed in a purpose built Perspex environmental chamber maintained at 37 °C using a heater unit constructed in-house (CR-UK Research Services). Images were collected using a CCD camera using × 63 plan-apochromat Phase 3 oil-immersion objective, numerical aperture 1.4 (Carl Zeiss) at 1 min intervals for a total of 1000 cycles. Representative still frames were extracted from the record for illustrative purposes and the complete series of images was compiled into movie files.
FACS analysis for cells with sub-G1 DNA content
MCF10A cells were treated in triplicate with FasL/CHX as indicated to induce apoptosis and harvested by scraping into PBS. Cells were fixed with ice cold 70% ethanol, then washed twice in 0.2 M disodium phosphate, 4 mM citric acid, pH 7.8 and treated with 50 μl of 100 μg/ml RNase followed by 200 μl of 50 μg/ml propidium iodide (PI). Cells were then analyzed by FACS for DNA content. 10 000 events were acquired and data analysis was preformed using FlowJo software (TreeStar Inc.).
Immunoprecipitation and western blotting
MCF10A cells were treated with FasL/CHX and lysed in 1% CHAPS buffer: 50 mM Tris–HCl, 150 mM NaCl, 1% CHAPS, 2 mM EDTA, 5% glycerol, 1 × Complete protease inhibitors (Roche), pH 8.0. Lysates were clarified by centrifugation at 10 000 g and 10% of the sample reserved for analysis by SDS-PAGE followed by western blotting with anti-caspase 8 1C12, anti-caspase 3 3G2, anti-active caspase 3, anti-caspase 9 (Cell Signaling Technology), anti-Bid (FL195, Santa Cruz) and anti-PARP (BD). Conformationally active Bax was immunoprecipitated with cell lysates using anti-Bax N20-coupled agarose beads (Santa Cruz) and anti-Bax α7/α8, BH2 domain (Oncogene). Active Bak was immunoprecipitated with anti-Bak NT (Upstate). Immunoprecipitates were subjected to western blot analysis using anti-Bax 2D2 (Merck) and anti-Bak NT. Replicate samples from the same experiment were used for the cell viability analysis (Figure 2b) and IP/westerns (Figure 2c and 3a).
MCF10A cells were seeded onto glass coverslips and 24 h later were treated with FasL/CHX as indicated. Cells were then fixed in 3% PFA, permeabilized with 0.1% Triton X-100, blocked with 0.2% fish skin gelatin and immunostained. Primary antibodies were anti-Cyt-c (BD) and anti-Bax N20 (Santa Cruz). Secondary antibodies were Cy-3 conjugated anti-mouse IgG and FITC-conjugated anti-rabbit IgG (Jackson ImmunoResearch). Coverslips were mounted onto glass slides using ProLong anti-fade reagent (Molecular Probes) and imaged using a LSM510 confocal microscopy fitted with a 63X/1.4 plan-apochromat Phase 3 oil immersion objective (Carl Zeiss).
Size exclusion chromatography
MCF10A cells were harvested by scraping into PBS, pelleted at 2000 r.p.m. and lysed in an equal volume of 2% CHAPS lysis buffer (without glycerol). Following rotation at 4 °C for 20 min, samples were clarified by spinning at 21 000 × g for 20 min and 40 μl loaded onto a pre-equilibrated Superdex 200 Precision Column PC 3.2/30 (2.4 ml; Pharmacia). The column was calibrated using thyroglobulin (667 kD), ferritin (440 kD), aldolase (158 kD), BSA (67 kD), ovalbumin (43 kD), chymotrypsinogen A (25 kD) and ribonuclease A (14 kD). The entire column volume was collected in 40 μl fractions and 10 μl analyzed by SDS PAGE.
MCF10A cells were grown on Thermanox plastic coverslips (Agar scientific) and following induction of apoptosis cells were fixed in a modified Karnovsky's fixative (4% paraformaldehyde, 2.5%. glutaraldehyde, 2 mM CaCl2 in 0.1 M Na cacodylate, pH7.4) and processed on the coverslips. Cells were washed in cacodylate buffer and post-fixed using 1% osmium tetroxide, 1% potassium ferricyanide in 0.1 M Na cacodylate pH7.4. Cells were washed again and 2% aqueous uranyl acetate solution was added for contrast enhancement. Cells were washed and then dehydrated by processing through a graded series of ethanol and then propylene oxide and then left in infiltrate with 50/50 mixture of araldite/propylene oxide overnight at room temperature. The next day infiltration was continued with 3 × 1 h changes of araldite alone (the samples were warmed to 60 °C for about 10 min before each change). Samples were then left to polymerize at 60 °C overnight. Sections of ∼90 nm thickness were cut on a Leica Ultracut S Ultratome (Leica) and collected on 200-mesh copper grids. Sections were further stained with a saturated solution of uranyl acetate in methanol for ∼6 min at RT, rinsed 4 × in methanol and then with Reynold's lead citrate stain for 4 min RT and rinsed 4 × in water. Samples were viewed in a JEOL 1200 TEM (JEOL). Each micrograph collected represented a different cell selected at random from the grid. At least 20 cells were examined in each sample and all mitochondria appearing in the micrographs were scored for ultrastructural morphology.
mitochondrial membrane potential
tetramethylrhodamine ethyl ester
Danial NN, Korsmeyer SJ . Cell death: critical control points. Cell 2004; 116: 205–219.
Nechushtan A, Smith CL, Hsu YT, Youle RJ . Conformation of the Bax C-terminus regulates subcellular location and cell death. EMBO J 1999; 18: 2330–2341.
Griffiths GJ, Dubrez L, Morgan CP, Jones NA, Whitehouse J, Corfe BM et al. Cell damage-induced conformational changes of the pro-apoptotic protein Bak in vivo precede the onset of apoptosis. J Cell Biol 1999; 144: 903–914.
Nechushtan A, Smith CL, Lamensdorf I, Yoon SH, Youle RJ . Bax and Bak coalesce into novel mitochondria-associated clusters during apoptosis. J Cell Biol 2001; 153: 1265–1276.
Chen L, Willis SN, Wei A, Smith BJ, Fletcher JI, Hinds MG et al. Differential targeting of prosurvival Bcl-2 proteins by their BH3-only ligands allows complementary apoptotic function. Mol Cell 2005; 17: 393–403.
Kuwana T, Bouchier-Hayes L, Chipuk JE, Bonzon C, Sullivan BA, Green DR et al. BH3 domains of BH3-only proteins differentially regulate Bax-mediated mitochondrial membrane permeabilization both directly and indirectly. Mol Cell 2005; 17: 525–535.
Willis SN, Fletcher JI, Kaufmann T, van Delft MF, Chen L, Czabotar PE et al. Apoptosis initiated when BH3 ligands engage multiple Bcl-2 homologs, not Bax or Bak. Science 2007; 315: 856–859.
Willis SN, Chen L, Dewson G, Wei A, Naik E, Fletcher JI et al. Proapoptotic Bak is sequestered by Mcl-1 and Bcl-xL, but not Bcl-2, until displaced by BH3-only proteins. Genes & Dev 2005; 19: 1294–1305.
Hsu YT, Wolter KG, Youle RJ . Cytosol-to-membrane redistribution of Bax and Bcl-X(L) during apoptosis. Proc Nat Acad Sci USA 1997; 94: 3668–3672.
Chen YB, Seo SY, Kirsch DG, Sheu TT, Cheng WC, Hardwick JM . Alternate functions of viral regulators of cell death. Cell Death Different 2006; 13: 1318–1324.
Cuconati A, White E . Viral homologs of BCL-2: role of apoptosis in the regulation of virus infection. Genes & Dev 2002; 16: 2465–2478.
Sundararajan R, Cuconati A, Nelson D, White E . Tumor necrosis factor-alpha induces Bax-Bak interaction and apoptosis, which is inhibited by adenovirus E1B 19 K. J Biol Chem 2001; 276: 45120–45127.
Wasilenko ST, Banadyga L, Bond D, Barry M . The vaccinia virus F1L protein interacts with the proapoptotic protein Bak and inhibits Bak activation. J Virol 2005; 79: 14031–14043.
Postigo A, Cross JR, Downward J, Way M . Interaction of F1L with the BH3 domain of Bak is responsible for inhibiting vaccinia-induced apoptosis. Cell Death Different 2006; 13: 1651–1662.
Arnoult D, Bartle LM, Skaletskaya A, Poncet D, Zamzami N, Park PU et al. Cytomegalovirus cell death suppressor vMIA blocks Bax- but not Bak-mediated apoptosis by binding and sequestering Bax at mitochondria. Proc Nat Acad Sci USA 2004; 101: 7988–7993.
Poncet D, Larochette N, Pauleau AL, Boya P, Jalil AA, Cartron PF et al. An anti-apoptotic viral protein that recruits Bax to mitochondria. J Biol Chem 2004; 279: 22605–22614.
Su J, Wang G, Barrett JW, Irvine TS, Gao X, McFadden G . Myxoma virus M11L blocks apoptosis through inhibition of conformational activation of Bax at the mitochondria. J Virol 2006; 80: 1140–1151.
Kvansakul M, van Delft MF, Lee EF, Gulbis JM, Fairlie WD, Huang DC et al. A structural viral mimic of prosurvival Bcl-2: a pivotal role for sequestering proapoptotic Bax and Bak. Mol Cell 2007; 25: 933–942.
Perez D, White E . TNF-alpha signals apoptosis through a bid-dependent conformational change in Bax that is inhibited by E1B 19K. Mol Cell 2000; 6: 53–63.
Sundararajan R, White E . E1B 19 K blocks Bax oligomerization and tumor necrosis factor alpha-mediated apoptosis. J Virol 2001; 75: 7506–7516.
Cuconati A, Degenhardt K, Sundararajan R, Anschel A, White E . Bak and Bax function to limit adenovirus replication through apoptosis induction. J Virol 2002; 76: 4547–4558.
Hackenbrock CR . Ultrastructural bases for metabolically linked mechanical activity in mitochondria. I. Reversible ultrastructural changes with change in metabolic steady state in isolated liver mitochondria. J Cell Biol 1966; 30: 269–297.
Hackenbrock CR . Ultrastructural bases for metabolically linked mechanical activity in mitochondria. II. Electron transport-linked ultrastructural transformations in mitochondria. J Cell Biol 1968; 37: 345–369.
Rossignol R, Gilkerson R, Aggeler R, Yamagata K, Remington SJ, Capaldi RA . Energy substrate modulates mitochondrial structure and oxidative capacity in cancer cells. Cancer Res 2004; 64: 985–993.
Sheridan JW, Bishop CJ, Simmons RJ . Biophysical and morphological correlates of kinetic change and death in a starved human melanoma cell line. J Cell Sci 1981; 49: 119–137.
Gottlieb E, Armour SM, Thompson CB . Mitochondrial respiratory control is lost during growth factor deprivation. Proc Natl Acad Sci U S A 2002; 99: 12801–12806.
Scorrano L, Ashiya M, Buttle K, Weiler S, Oakes SA, Mannella CA et al. A distinct pathway remodels mitochondrial cristae and mobilizes cytochrome c during apoptosis. Develop Cell 2002; 2: 55–67.
Greenawalt JW, Rossi CS, Lehninger AL . Effect of active accumulation of calcium and phosphate ions on the structure of rat liver mitochondria. J Cell Biol 1964; 23: 21–38.
Pivovarova NB, Nguyen HV, Winters CA, Brantner CA, Smith CL, Andrews SB . Excitotoxic calcium overload in a subpopulation of mitochondria triggers delayed death in hippocampal neurons. J Neurosci 2004; 24: 5611–5622.
Gross A, Jockel J, Wei MC, Korsmeyer SJ . Enforced dimerization of BAX results in its translocation, mitochondrial dysfunction and apoptosis. EMBO J 1998; 17: 3878–3885.
Annis MG, Soucie EL, Dlugosz PJ, Cruz-Aguado JA, Penn LZ, Leber B et al. Bax forms multispanning monomers that oligomerize to permeabilize membranes during apoptosis. EMBO J 2005; 24: 2096–2103.
Huang Q, Petros AM, Virgin HW, Fesik SW, Olejniczak ET . Solution structure of the BHRF1 protein from Epstein–Barr virus, a homolog of human Bcl-2. J Mol Biol 2003; 332: 1123–1130.
Uren RT, Dewson G, Chen L, Coyne SC, Huang DC, Adams JM et al. Mitochondrial permeabilization relies on BH3 ligands engaging multiple prosurvival Bcl-2 relatives, not Bak. J Cell Biol 2007; 177: 277–287.
Ott M, Robertson JD, Gogvadze V, Zhivotovsky B, Orrenius S . Cytochrome c release from mitochondria proceeds by a two-step process. Proc Natl Acad Sci USA 2002; 99: 1259–1263.
Germain M, Mathai JP, McBride HM, Shore GC . Endoplasmic reticulum BIK initiates DRP1-regulated remodelling of mitochondrial cristae during apoptosis. EMBO J 2005; 24: 1546–1556.
Pinton P, Rizzuto R . Bcl-2 and Ca2+ homeostasis in the endoplasmic reticulum. Cell Death Differ 2006; 13: 1409–1418.
Hardie DG, Hawley SA, Scott JW . AMP-activated protein kinase – development of the energy sensor concept. J Physiol 2006; 574: 7–15.
Robb-Gaspers LD, Burnett P, Rutter GA, Denton RM, Rizzuto R, Thomas AP . Integrating cytosolic calcium signals into mitochondrial metabolic responses. EMBO J 1998; 17: 4987–5000.
Pacher P, Hajnoczky G . Propagation of the apoptotic signal by mitochondrial waves. EMBO J 2001; 20: 4107–4121.
Szabadkai G, Simoni AM, Chami M, Wieckowski MR, Youle RJ, Rizzuto R . Drp-1-dependent division of the mitochondrial network blocks intraorganellar Ca2+ waves and protects against Ca2+-mediated apoptosis. Mol Cell 2004; 16: 59–68.
We thank Colin Gray for assistance with live cell video microscopy, Olga O'Neill for assistance with size exclusion chromatography and members of the Signal Transduction Laboratory for helpful comments and suggestions.
About this article
Cite this article
Cross, J., Postigo, A., Blight, K. et al. Viral pro-survival proteins block separate stages in Bax activation but changes in mitochondrial ultrastructure still occur. Cell Death Differ 15, 997–1008 (2008). https://doi.org/10.1038/cdd.2008.14
- mitochondrial ultrastructure
Specific Features of Apoptotic Signaling Regulation in Cells Infected with Cytomegalovirus and Epstein–Barr Virus
Biology Bulletin Reviews (2018)
Frontiers in Microbiology (2018)
Journal of Biotechnology (2015)
Dissecting the roles of E1A and E1B in adenoviral replication and RCAd-enhanced RDAd transduction efficacy on tumor cells
Cancer Biology & Therapy (2014)